Full data from Alnylam's pivotal givosiran programme show a big impact for severe patients, though a case still needs to be made for a broader population.
The RNAi specialist gets an $800m cash injection under a central nervous system tie-up with Regeneron.
High-profile presentations from the likes of Intercept and Alnylam remain under wraps before Europe’s biggest liver disease conference next month, but the early abstract…
Alnylam looks likely to get approval for its second RNAi candidate, givosiran. But toxicity issues have tainted the Envision trial win.
Duchenne muscular dystrophy attracts a new entrant in pamrevlumab, while Alnylam awaits more pivotal data with givosiran.
Was 2018 as good as it gets for drug approvals, or is the pipeline so stellar that even a US government shutdown cannot stop biopharma?
Alnylam appears to have turned its Onpattro launch around, but is adamant that investors should have been more patient all along.
Vantage publishes its annual look ahead to 2019, examining the trends and issues that will shape biopharma in the coming year.
Trailing the leaders in amyloidosis and Nash, the respective small caps Eidos and Conatus look to mid-stage trial readouts to demonstrate their relevance.